Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of RMC-035 to Prevent Acute Kidney Injury After High-Risk Open-Chest Cardiac Surgery
2021-004040-19Phase 2Completed
- Sponsor
- Guard Therapeutics
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF), cardiac surgery-associated acute kidney injury (CSA-AKI) and cardiac morbidity comparing RMC-035 with Placebo (2 arms). Started Nov 2021; status: completed.
02
Drugs
RMC-035
03
Conditions
acute kidney failure (AKF)cardiac surgery-associated acute kidney injury (CSA-AKI)cardiac morbidity
Beyond the preview
Go deeper on 2021-004040-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004040-19.